Qiang Lu

Cofounder and chairman of GenFleet Therapeutics Inc

Execute President of SDDA Committee

Dr. Qiang Lu is cofounder and chairman of GenFleet Therapeutics Inc., a Shanghai based biotech company focusing on the next generation of immuno-oncology and autoimmune drug development.

While serving for various pharmaceutical or biotech companies, Dr. Lu had championed numerous R&D projects, including PD-L1 antibody, MEK1 inhibitor, URAT1 inhibitor (at CStone Pharmaceuticals as SVP of Operation), PD-1 antibody (at Gloria Pharmaceuticals as CSO, with ex-China rights transferred to Arcus Biosci.), Orexin antagonist YZJ-1139 and EGFR/T790M inhibitor YZJ-0318 (at Yangtze River Pharmaceuticals as CSO), among others.

Dr. Lu also founded WuXi AppTec’s Discovery Biology and WuXi Biologics business units, as VP of Research. Prior to that, Dr. Lu worked in US at Wyeth and Novartis, respectively, as a project leader and a platform leader, respectively.